First-in-human phase I trial of anti-hepatocyte growth factor antibody (YYB101) in refractory solid tumor patients

Background: YYB101, a humanized monoclonal antibody against hepatocyte growth factor (HGF), has shown safety and efficacy in vitro and in vivo . This is a first-in-human trial of this antibody. Materials and Methods: YYB101 was administered intravenously to refractory cancer patients once every 4 we...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Hoofdauteurs: Seung Tae Kim, Jung Yong Hong, Se Hoon Park, Joon Oh Park, Young Whan Park, Neunggyu Park, Hukeun Lee, Sung Hee Hong, Song-Jae Lee, Seong-Won Song, Kyung Kim, Young Suk Park, Ho Yeong Lim, Won Ki Kang, Do-Hyun Nam, Jeong-Won Lee, Keunchil Park, Kyoung-Mee Kim, Jeeyun Lee
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: SAGE Publishing 2020-06-01
Reeks:Therapeutic Advances in Medical Oncology
Online toegang:https://doi.org/10.1177/1758835920926796
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items